Company Performance Metrics
Arriva Pharmaceuticals, Inc., founded in 1997, is a privately held biopharmaceutical company focused on the development and commercialization of recombinant protease inhibitors for treatment of a wide range of human diseases. The areas of therapeutic focus are:
- Respiratory diseases: hereditary emphysema, asthma, chronic obstructive pulmonary
disorder (COPD) and cystic fibrosis.
- Dermatological diseases: atopic dermatitis, psoriasis.
- Inflammatory ear diseases: otitis media, otitis externa.
- Oncology: breast cancer, prostate cancer.
The company has developed technology for large-scale production of stable, non-animal sourced recombinant proteins in yeast. Using this technology, GMP, Good Manufacturing Practice, clinical grade recombinant alpha 1-antitrypsin (AAT) has been produced for clinical trials for respiratory and dermatological indications and maspin will be produced for treatment of breast and prostate cancer.
In January, 2001 the company changed its name from AlphaOne Pharmaceuticals, Inc. to Arriva Pharmaceuticals, Inc. to reflect an expansion from a single product focus to a more diversified drug product pipeline.
